Yarrow Bioscience (VYNE) director discloses 87,820 options
Rhea-AI Filing Summary
Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports that director Steven L. Hoerter holds a stock option to buy 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036.
The option was assumed in a merger effective July 27, 2026, converting prior Yarrow options into options on Issuer Common Stock on the same terms. One quarter of this option vests on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to Hoerter’s continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hoerter Steven L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 87,820 shares (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying option shares: 87,820 shares
Exercise price: $6.19 per share
Par value: $0.0001 per share
+3 more
6 metrics
Underlying option shares
87,820 shares
Shares of Issuer Common Stock underlying Steven L. Hoerter’s stock option holding
Exercise price
$6.19 per share
Exercise price of the Stock Option (Right to Buy) on Issuer Common Stock
Par value
$0.0001 per share
Par value of the Issuer Common Stock underlying the reported stock option
Merger Effective Time
July 27, 2026
Date when a VYNE subsidiary merged with and into Yarrow Bioscience, Inc.
Option expiration
April 17, 2036
Expiration date of the stock option assumed in the merger
Initial vesting date
April 17, 2027
One quarter of the 87,820-share option vests on this date
Key Terms
Effective Time, Merger, Issuer Common Stock, Stock Option (Right to Buy
4 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the Effective Time), a subsidiary merged with Yarrow"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
Merger regulatory
"A wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
Issuer Common Stock financial
"Represents options to purchase shares of common stock of the Issuer (Issuer Common Stock)"
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) reported as a derivative holding by the director"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option holding does VYNE/Yarrow director Steven L. Hoerter report?
Steven L. Hoerter reports holding a stock option for 87,820 shares of Yarrow Bioscience Issuer Common Stock at an exercise price of $6.19 per share. The option expires on April 17, 2036 and was assumed in connection with the Yarrow–VYNE merger.
How did the Yarrow–VYNE merger affect director equity reported for VYNE?
At the merger’s Effective Time on July 27, 2026, a VYNE subsidiary merged into Yarrow, which became a wholly owned subsidiary. VYNE then changed its name to Yarrow Bioscience, Inc., and existing Yarrow options held by Hoerter were converted into options on Issuer Common Stock.
What are the key terms of the Issuer Common Stock underlying VYNE’s reported option?
The option covers Issuer Common Stock with a par value of $0.0001 per share. It is a Stock Option (Right to Buy) with an exercise price of $6.19 per share, expiring on April 17, 2036, and reflects assumed pre-merger Yarrow options.
Does the Form 3 for VYNE/Yarrow show any recent insider purchases or sales?
No insider purchases or sales are reported; the filing lists a holding entry for a stock option. The Form 3 describes existing derivative ownership following the merger, rather than new buy or sell transactions, and shows 87,820 underlying shares held directly.